Desipramine Interactions

Tricyclic antidepressant that causes striking and sustained increases in brain d-amphetamine concentration with potentiated cardiovascular effects.

Source: NLP:amphetamine sulfate

Bupropion increased desipramine Cmax, AUC, and t1/2 by approximately 2-, 5-, and 2-fold, respectively; effect persisted for at least 7 days after last bupropion dose.

Source: NLP:bupropion hydrochloride

Methylphenidate may inhibit the metabolism of desipramine. Downward dose adjustments may be required and plasma drug concentration should be monitored.

Source: NLP:dexmethylphenidate hydrochloride

Amphetamines enhance activity of desipramine causing striking and sustained effects.

Source: NLP:dextroamphetamine

Tricyclic antidepressant may enhance activity causing striking sustained increases in d-amphetamine concentration and potentiated cardiovascular effects. Monitor frequently and adjust therapy as needed.

Source: NLP:dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate

Tricyclic antidepressant causing striking sustained increases in brain d-amphetamine concentration and potentiated cardiovascular effects.

Source: NLP:dextroamphetamine sulfate

Exposure increases 8-fold. Reduce desipramine dose and adjust based on clinical response.

Source: NLP:dextromethorphan hydrobromide and quinidine sulfate

Co-administration can cause severe, prolonged hypertension. Monitor for hypertension if norepinephrine bitartrate cannot be avoided.

Source: NLP:norepinephrine bitartrate

CYP2D6 inhibitor that increases propafenone plasma levels, potentially leading to cardiac arrhythmias and proarrhythmia risk.

Source: NLP:propafenone hydrochloride

Steady state plasma concentrations of desipramine can increase by approximately 20% when coadministered with alprazolam up to 4 mg/day. Clinical significance unknown.

Source: NLP:alprazolam

CYP2D6 substrate antidepressant. Bupropion inhibits CYP2D6, increasing desipramine exposure. Dose reduction may be necessary.

Source: NLP:bupropion hcl er (xl)

CYP2D6 substrate; cinacalcet is a strong CYP2D6 inhibitor. Dose adjustment may be required for concomitant CYP2D6-metabolized medications.

Source: NLP:cinacalcet

Cinacalcet is a strong CYP2D6 inhibitor. Dose adjustments may be required for concomitant CYP2D6 substrate medications.

Source: NLP:cinacalcet hydrochloride

Desvenlafaxine increases desipramine levels. Reduce dose by up to one-half with 400 mg desvenlafaxine; no adjustment needed with 100 mg or lower.

Source: NLP:desvenlafaxine

Desvenlafaxine increases desipramine exposure. Reduce dose by up to one-half with 400 mg desvenlafaxine; no adjustment needed with 100 mg or lower.

Source: NLP:desvenlafaxine er

Concomitant use increases exposure (Cmax and AUC). Reduce dose by up to one-half if co-administered with 400 mg desvenlafaxine.

Source: NLP:desvenlafaxine succinate

Concomitant use may potentiate the cardiovascular effects of dopamine, including hypertension.

Source: NLP:dopamine hydrochloride

Coadministration resulted in 40% increase in desipramine Cmax. Desipramine is a CYP2D6 substrate metabolized by escitalopram.

Source: NLP:escitalopram

Methylphenidate may inhibit metabolism of this tricyclic drug. Downward dose adjustments may be required and plasma concentrations should be monitored.

Source: NLP:methylphenidate

Potent CYP2D6 inhibitor may increase plasma concentration of metoprolol, decreasing cardioselectivity.

Source: NLP:metoprolol

Potent CYP2D6 inhibitor may increase metoprolol plasma concentration, decreasing cardioselectivity.

Source: NLP:metoprolol tartrate

Additive tachycardia, hypertension, and drowsiness reported with concurrent use.

Source: NLP:nabilone

Tricyclic antidepressant may cause dry mouth and diminished salivary secretions, making sublingual nitroglycerin dissolution difficult.

Source: NLP:nitroglycerin

Paroxetine inhibits CYP2D6, increasing desipramine exposure. Decrease desipramine dosage if needed with concomitant paroxetine use.

Source: NLP:paroxetine

Paroxetine inhibits CYP2D6, increasing exposure of desipramine. Dosage reduction may be needed.

Source: NLP:paroxetine hydrochloride

Paroxetine inhibits CYP2D6 metabolism of desipramine, potentially increasing desipramine levels.

Source: NLP:paroxetine hydrochloride hemihydrate

Terbinafine inhibits CYP450 2D6, resulting in 2-fold increase in Cmax and 5-fold increase in AUC of desipramine. Effects persist up to 4 weeks after discontinuation. Monitor and may require dose reduction.

Source: NLP:terbinafine

Terbinafine inhibits CYP450 2D6 metabolism, resulting in 2-fold increase in Cmax and 5-fold increase in AUC. Effects persist for 4 weeks after discontinuation. Careful monitoring and dose reduction may be required.

Source: NLP:terbinafine hydrochloride

Terbinafine inhibits CYP450 2D6, resulting in 2-fold increase in Cmax and 5-fold increase in AUC of desipramine. Effects persist for 4 weeks after discontinuation.

Source: NLP:terbinafine tablets 250 mg

In vitro and in vivo studies showed tolcapone did not change desipramine pharmacokinetics or affect hemodynamic parameters when given with levodopa/carbidopa.

Source: NLP:tolcapone